治疗后肿瘤ADC对高危前列腺癌根治性放疗的预测价值
本研究回顾性分析186例接受根治性放疗联合雄激素剥夺治疗的高危前列腺癌患者,评估治疗后DW-MRI来源的表观扩散系数(ADC)的预后价值。中位随访10.7年,10年无进展生存率和前列腺癌特异性生存率分别为79.2%和82.3%。较低的治疗后ADC及ADC升高幅度有限与更差结局显著相关。
要点
- 治疗后ADC高者PFS和PCSS均显著优于ADC低者
- ADC反应高同样预测更好的PFS和PCSS
- 高PSA、高ISUP分级、短ADT疗程和低治疗后ADC为进展的独立相关因素
核心结论
- 治疗后ADC及其变化是有前景的无创生物标志物,可用于高危前列腺癌长期结局预测,并可能改善治疗后风险分层与个体化管理。
研究设计与样本
- 回顾性队列研究,纳入2012至2023年间治疗的186例高危前列腺癌患者。
- 所有患者均接受治疗前后DW-MRI用于分期、放疗计划和疗效评估。
- 患者接受前列腺及盆腔野放疗、ADT至少12个月,最短随访24个月。
- 主要终点为无进展生存期(PFS)和前列腺癌特异性生存期(PCSS)。
主要发现
- 治疗后DW-MRI中位检查时间为4.1个月,94%患者肿瘤ADC升高。
- 基线肿瘤ADC与疾病进展无显著关联,而较低的治疗后ADC和有限的ADC升高与更差结局显著相关。
- 中位随访10.7年,10年PFS和PCSS分别为79.2%和82.3%。
- 高治疗后ADC与更优PFS(89.1% vs. 61.7%;p < 0.001)和PCSS(87.7% vs. 69.7%;p = 0.009)相关。
- 高ADC反应预测更优PFS(88.4% vs. 57.1%;p = 0.001)和PCSS(89.0% vs. 71.5%;p = 0.04)。
关键数值与推荐
- 高治疗后ADC组PFS为89.1%,低组为61.7%(p < 0.001)。
- 高治疗后ADC组PCSS为87.7%,低组为69.7%(p = 0.009)。
- 高ADC反应组PFS为88.4%,低组为57.1%(p = 0.001)。
- 高ADC反应组PCSS为89.0%,低组为71.5%(p = 0.04)。
临床怎么用
- 治疗后DW-MRI测量的ADC及其变化可用于高危前列腺癌放疗后的风险分层。
- 对治疗后ADC低或ADC升高有限者,可考虑加强随访或个体化管理。
局限性
- 为单中心回顾性队列研究,样本量186例,结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the prognostic value of post-treatment apparent diffusion coefficient (ADC) derived from diffusion-weighted magnetic resonance imaging (DW-MRI) in high-risk prostate cancer (PCa) patients treated with definitive radiotherapy (RT) and androgen deprivation therapy (ADT). MATERIALS AND METHODS: A retrospective cohort of 186 high-risk PCa patients treated between 2012 and 2023 was analyzed. All underwent pre- and post-treatment DW-MRI for staging, RT planning, and response assessment. Each patient received prostate and pelvic field RT, underwent ADT for at least 12 months, and had a minimum follow-up period of 24 months. Primary endpoints were progression-free survival (PFS) and prostate cancer-specific survival (PCSS). RESULTS: Post-treatment DW-MRI, performed at a median of 4.1 months, showed increased tumor ADC in 94 % of patients. While baseline tumor ADC values were not significantly associated with disease progression, lower post-treatment ADC and limited ADC increase were significantly correlated with worse outcomes. At a median follow-up of 10.7 years, 10-year PFS and PCSS rates were 79.2 % and 82.3 %, respectively. High post-treatment ADC was associated with superior PFS (89.1 % vs. 61.7 %; p < 0.001) and PCSS (87.7 % vs. 69.7 %; p = 0.009). High ADC response also predicted better PFS (88.4 % vs. 57.1 %; p = 0.001) and PCSS (89.0 % vs. 71.5 %; p = 0.04). Low PSA and high ADC response predicted better PFS, while simultaneous integrated boost improved PCSS. High PSA, high ISUP grade, short ADT duration, and low post-treatment ADC were independently associated with progression. CONCLUSIONS: Post-treatment ADC and its changes are promising non-invasive biomarkers for long-term outcome prediction in high-risk PCa. Integration of DW-MRI-derived ADC analysis may enhance post-treatment risk stratification and guide personalized management.
引用
- Onal C, Erbay G, Guler OC, et al. Predictive utility of Post-Treatment tumor apparent diffusion coefficient in High-Risk prostate cancer undergoing definitive Radiotherapy: A Long-Term outcome analysis. Radiother Oncol. 2025. PMID: 40789426. doi:10.1016/j.radonc.2025.111090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。